Valiant Organics Limited reported a profit after tax of ₹34.36 crore for the financial year ended March 31, 2026, marking a significant turnaround from a loss of ₹3.00 crore in the previous year.

The speciality chemicals manufacturer disclosed these figures during its 21st Annual General Meeting held on September 29, 2026, via video conferencing. Revenue from operations for FY26 stood at ₹738.38 crore, while EBITDA reached ₹100.80 crore, reflecting an EBITDA margin of 13.65%.

Financial Performance Highlights

The company highlighted improvements in profitability and margins alongside operational efficiencies undertaken during the fiscal year. Key financial metrics for FY26 are summarized below:

Strategic Focus and Operations

Navin C. Shah, Chairperson of the company, addressed shareholders on the operating performance, emphasizing the focus on improving capacity utilisation and operating efficiencies. The management prioritized higher-value products and import-substitution opportunities as part of its strategic roadmap. Additionally, the company outlined prudent capital allocation strategies to support future growth.

Mahek M. Chheda, Executive Director and Chief Financial Officer, presented an overview of the company’s manufacturing footprint, key chemistries, and product portfolio. The presentation underscored strengths in the pharmaceutical intermediates business, along with safety and environmental initiatives.

AGM Proceedings and Resolutions

The meeting was attended by 51 members through video conferencing. The requisite quorum was present, and the proceedings were deemed to have been conducted at the registered office. The following key resolutions were taken up:

• Adoption of audited standalone and consolidated financial statements for FY26.
• Re-appointment of directors Nemin M. Savadia and Santosh S. Vora, who retired by rotation.
• Ratification of remuneration for the cost auditor for FY27.
• Shifting of the registered office within Maharashtra.
• Revision in terms of appointment for Managing Director Sathiababu K. Kallada and other executive directors.
• Approval of material related party transactions with entities including Aarti Industries Limited and Valiant Laboratories Limited.

What the Numbers Show

The shift from a net loss of ₹3.00 crore in FY25 to a net profit of ₹34.36 crore in FY26 indicates a substantial improvement in bottom-line performance. With an EBITDA margin of 13.65% on revenue of ₹738.38 crore, the company demonstrated enhanced operational leverage compared to the previous year's deficit position.

Valiant Organics Limited reported a net profit of ₹34 crore in FY26, reversing two consecutive years of losses, as EBITDA climbed to ₹101 crore on revenue of ₹739 crore.

The company presented these results at its 21st Annual General Meeting held on September 29, 2026. The presentation was submitted to BSE and the National Stock Exchange of India under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. As on March 31, 2026, Valiant Organics carried a market capitalisation of ₹~567 crore.

Financial performance across FY23 to FY26

The following table captures the company's key consolidated financial metrics over four fiscal years.

FY26 EBITDA of ₹101 crore and a margin of 13.64% represent a marked recovery from FY24's low of ₹42 crore and 6.20% margin. The return on capital employed rose to 8.02% in FY26 from 3.42% in FY25, while return on equity turned positive at 4.48% after two years in negative territory.

What the numbers show

Revenue contracted from ₹912 crore in FY23 to ₹677 crore in FY24 before recovering to ₹719 crore in FY25 and ₹739 crore in FY26. Profitability followed a sharper trajectory: PAT fell from ₹76 crore in FY23 to a loss of ₹3 crore in each of FY24 and FY25, then recovered to ₹34 crore in FY26. Net worth, which had declined from ₹585 crore in FY23 to ₹570 crore in FY25, edged back up to ₹588 crore in FY26. Net debt to equity remained stable at 0.33x across FY25 and FY26.

FY26 revenue composition

Hydrogen-based chemistries dominated the revenue mix, with Hydrogenation accounting for the largest share. The breakdown by chemistry and end-user industry is presented below.

Operations and manufacturing footprint

Valiant Organics was incorporated in 1984 and is headquartered in Mumbai. The company manufactures specialty chemicals serving agrochemicals, pharmaceuticals, dyes, pigments, and veterinary medications. It operates 6 manufacturing units across 5 locations with a total production capacity of 80,000 TPA, and maintains 5 Zero Liquid Discharge plants. The workforce stands at 900+ employees.

The manufacturing units span Gujarat and Maharashtra, with capacities and primary products as follows:

The company positions itself as one of the largest chlorophenol derivatives manufacturers globally, one of the largest domestic Para Nitro Aniline (PNA) manufacturers, and among the first few domestic Para Amino Phenol (PAP) manufacturers. It also describes itself as one of the few commercial players in Ortho Anisidine and Para Anisidine.

Note: Pursuant to the allotment of further equity shares through the IPO by the company's material step-down subsidiary Valiant Laboratories Limited, the stake of subsidiary Dhanvallabh Ventures LLP in Valiant Laboratories Limited was diluted to 46.83%, and accordingly Valiant Laboratories Limited ceased to be a step-down subsidiary and became an associate company with effect from October 4, 2023. Consolidated financials of previous periods and year-to-date results are therefore not comparable.